Focus: ResMed is a $4.2B public medical device company headquartered in San Diego specializing in cloud-connected devices and software for respiratory, sleep, and cardiopulmonary conditions. The company dominates the positive airway pressure (PAP) and non-invasive ventilation markets with a global installed base across home and acute care settings.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow ResMed to get notified when they start hiring — the background below is worth knowing for when they do.
Flagship market-leading CPAP device with cloud connectivity; represents core revenue driver in OSA market.
Help build intelligence for ResMed
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from ResMed's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Advanced ventilation therapy device addressing higher-acuity cardiopulmonary indications; Phase 4 study in heart failure indicates continued clinical validation.
Established COPD accessory product with recurring revenue model via device supplies and consumables.
JPMorgan Issues Overweight Rating for ResMed Amid Sleep Apnea Shift - HarianBasis.co
JPMorgan Issues Overweight Rating for ResMed Amid Sleep Apnea Shift HarianBasis.co
8-K Filing: Incannex Healthcare Inc. (IXHL) (CIK 0001873875) — CORPORATE PRESENTATION, DATED MARCH 12, 2026
CORPORATE PRESENTATION, DATED MARCH 12, 2026
Four ASX healthcare stocks which are looking cheap - The Motley Fool Australia
Four ASX healthcare stocks which are looking cheap The Motley Fool Australia
Sleep Tech Demand Fuels ResMed - AlphaStreet
Sleep Tech Demand Fuels ResMed AlphaStreet
Ozempic-style drugs prove to be 'a tailwind' for Resmed - AAP News
Ozempic-style drugs prove to be 'a tailwind' for Resmed AAP News
8-K Filing: RESMED INC (RMD, RSMDF) (CIK 0000943819) — EX-99.1
EX-99.1
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Obstructive sleep apnea, positive airway pressure therapy, and COVID-19 outcomes.
Geographical Variations in CPAP Termination Rates in Patients With OSA: Insights From the Nationwide Claims Data Lake for Sleep Apnoea (ALASKA) French Nationwide Data Set.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo